NEW YORK – Gilead Sciences on Tuesday said it has acquired San Diego-based biotech XinThera, including the selective PARP1 inhibitors in its pipeline.
According to Gilead, XinThera's PARP1 selective inhibitors could potentially have improved toxicity profiles versus first-generation PARP1/2 inhibitors and could be combined with DNA-damaging drugs like Gilead's Trodelvy (sacituzumab govitecan). The firm's PARP1 oncology agent, as well as an MK2-targeting inflammatory disease asset, could enter clinical trials this year, according to Gilead. XinThera is developing its PARP1 inhibitor XIN5104 for homologous recombination repair deficient solid tumors including breast, ovarian, prostate, and pancreatic cancers, among others.
The drugmakers did not disclose the financial details of the acquisition, though Gilead said it expects the XinThera transaction to reduce its GAAP and non-GAAP 2023 earnings per share by about $.12 to $.15.
"The team at XinThera has developed research assets with the potential to target the DNA damage repair pathway in treating cancer and direct the body's immune response in inflammatory diseases, both of which may improve outcomes for people living with these diseases," Gilead Executive VP of Research Flavius Martin said in a statement. "Guided by our scientific framework, this acquisition will allow us to further expand our early pipeline of diverse assets that will continue to fuel our durable late-phase portfolio."